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Abstract 
Alzheimer's dementia is a complex disorder in both its symptoms and its 
mechanisms. While it is not a normal part of aging, its prevalence 
increases exponentially with age. As the 'baby-boomer' generation begins 
to enter the 65+ demographic in the West, we can expect to see an 
unprecedented number of cases of Alzheimer's in the near future. This 
paper discusses the methods of diagnosing and treating individuals with 
Alzheimer's with respect to their rights as individuals. Methods of easing 
the burden of caregivers through counseling and drug therapy are also 
covered. The etiology of Alzheimer's is discussed from a chiefly biomedical 
perspective, with notable attention to the genetic factors leading to higher 
risk of developing Alzheimer's. Lastly, social and ethical issues including 
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quality of care, euthanasia, and current societal values are considered. 
Introduction 
Alzheimer's dementia was first described by Emil Kraepelin as a 
behavioural syndrome in the elderly. Klunemann, Fronhofer, Wurster, Fischer, 
Ibach, and Klein (2002) describe the case of Johann F., a patient at Kraeplin's 
hospital, who was diagnosed with “presenile dementia” in the late 1800's. This 
patient was later admitted to the care of Dr. Alois Alzheimer in a Bavarian clinic, 
where the neuropathology of the disease was first described. Alzheimer's 
meticulous autopsies revealed miliary plaques in the brain of Johann F. and 
others with similar behavioural symptoms (Katzman & Bick, 2000). His work 
was the first to link the physical symptoms of the disease to what is now the 
most common form of dementia, and Kraepelin accordingly named the disorder 
after Dr. Alzheimer.  
Alzheimer's is a primary dementia, meaning that the symptoms are a direct 
result of the disorder (Knox & Gekoski, 2003). The presence of this form of 
dementia is heralded initially by memory difficulties, beginning with poor 
memory for recent events. As the disorder progresses individuals with 
Alzheimer's begin to show language difficulties, sleep difficulties, agitation, 
helplessness, irritability and orientation difficulties. In the final stages of the 
disorder the individual is typically unable to properly communicate, becomes 
aggressive, performs repetitive actions, and is unable to care for themselves 
(Knox & Gekoski, 2003). This disorder greatly increases vulnerability to 
respiratory and cardiac disease as individuals near a vegetative state. 
Individuals suffering from Alzheimer's typically live only 10 years after the initial 
diagnosis. Over the later course of the disease these individuals require 
constant care: They sleep on disrupted cycles, and require supervision for their 
safety and those around them (Mace & Rabins, 1999). Alzheimer's is 
devastating not only for the sufferers, but also those around them and those 
who care for them.  
‘Normal' and Dementia  
In the study of abnormal psychology, dementia should be synonymous with 
abnormal. Nearly any aberration in cognitive function be it motor, executive, 
memory related or sensory qualifies as dementia (Knox & Gekoski, 2003). The 
word “dementia” itself refers to a state of being out of ones mind. This definition 
implies only that a ‘demented' individual has departed from a normal state of 
mind, though the word itself gives no hints as to what the proper state of mind 
should be. The vagueness of the term dementia leaves the expression open to 
interpretation. It can theoretically include anything cognitively abnormal, 
encompassing troublesome behaviour for which we have no better explanation. 
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This diagnostic loophole is crippling in that the diagnoses of dementias are 
based on using subjective perception of normal and applying that notion to 
others. In order to make a proper diagnosis of dementia, the individual (or body 
of individuals) making the diagnosis must collectively understand the difference 
between a normal state of mind and an abnormal one. This ambiguity is 
avoided in the practical sense. The diagnosis of all of the major dementias 
follows the etiology of diseases rather than the symptoms, allowing irrefutable 
diagnoses and sound approaches to treatments.  
While the theoretical notion of dementia is vague, the dementias in DSM-IV 
are a group of mental illnesses with specific causes (Knox & Gekoski, 2003). 
This circumvents the need to understand what is normal and what is deviant. 
Since Alzheimer's is a disease of aging, it specifically calls into question what is 
normal and what is abnormal behaviour in an aging individual. What a younger 
individual may perceive as cognitive abnormality could just be the natural 
benign forgetfulness that so often accompanies old age. The persistent 
inclusion of the dementias (and specifically Alzheimer's dementia) in the DSM, 
though the majority are biological diseases, stands as evidence that people are 
able to subjectively distinguish between normal and abnormal behaviour. The 
symptoms first described by Emil Kraepelin have since been solidly linked to 
biological factors (Katzman & Bick, 2000). Though psychologists may never be 
able to define what is normal and abnormal, the case of Alzheimer's dementia 
shows that humans are able to subjectively perceive and differentiate between 
normal and abnormal despite the theoretical difficulties of defining normal 
behaviour.  
Theories of Alzheimer's 
While no single cause has been elucidated as of yet, the theories and 
evidence of Alzheimer's pathology fall under the umbrella of biomedical theory. 
The risk factors for developing the disease based on epidemiological data 
involve chiefly physiological factors and diet (Knox & Gekoski, 2003). Genetic 
correlation with probability of developing disease and time of onset also support 
a biomedical model. Also, Raber, Huang and Ashford (2004) have shown that 
Alzheimer's dementia has largely invariable pathology, largely independent of 
ethnicity or cultural differences. The prevalence of Alzheimer's grows 
significantly with age, again indicating that there are physiological risk factors 
that compound in elderly patients. The biomedical model is perhaps supported 
most by changes in the actual morphology of the brain (Knox & Gekoski, 2003). 
Cortical shrinkage and ventricular expansion in Alzheimer's dementia have not 
been linked with any specific cause or effect of the disease, but indicate that 
Alzheimer's has biomedical associations (Knox & Gekoski, 2003; Carmichael et 
al., 2006). 
The correlation between education level and development of Alzheimer's 
dementia shown by Wilkosz, Miyahara, Lopez, DeKosky and Sweet (2006) 
suggests that the onset of the disorder may be more complicated than simply 
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genetics. This relationship has been contested by some however, and it 
remains controversial. If there is indeed a correlation, it could be that the 
biomedical model of Alzheimer's dementia is influenced by cognitive 
experience. Conversely, it could be interpreted as the cognitive decline being 
less noticeable in individuals with substantial educations. Alzheimer's dementia 
is almost definitely a disorder that can be explained by biomedical theory, but 
perhaps not to the exclusion of other theories. The relationship between 
cognitive experience and aging needs to be explored more thoroughly before 
any conclusions can be drawn.  
Diagnosis of Alzheimer's 
Dementia of the Alzheimer's type is catalogued in the DSM-IV as an axis I 
disorder (Knox & Gekoski, 2003). The key factor for diagnosing Alzheimer's and 
to a large degree other dementias is memory impairment. The individual must 
also exhibit dysfunction in one of four areas: Language (aphasia), motor 
function (apraxia), object recognition (agnosia), or planning, organizing, 
sequencing and abstracting (executive function) (American Psychiatric 
Association, 1994). For a positive diagnosis to be made, other types of 
dementias must first be ruled out. These include a variety of biological 
disorders with known causes, such as Parkinson's, Huntington's, HIV infection, 
cardiovascular disease, subdural haematoma, hydrocephalus, Creutzfeldt-
Jakob's disease, folic acid deficiency, chronic alcoholism, malnutrition, 
hypothyroidism, brain tumours or recent brain trauma. These factors can be 
relatively easily ruled out with brain imaging, genotyping and history tracing. 
This is an important step in the diagnosis of Alzheimer's, as these disorders 
cause dementias that are symptomatically similar. Another important aspect to 
a positive diagnosis of Alzheimer's is that there must be a cognitive decline 
(American Psychological Association, 1994). Events such as strokes or brain 
trauma cause cognitive impairment, but not the continual decline seen with 
neurodegenerative disorders. Symptoms of Alzheimer's dementia must also be 
persistent, and not over the course of passing delirium. If the dementia is better 
associated with another psychiatric disorder such as schizophrenia or major 
depressive disorder, again the diagnosis is made in favour of these disorders.  
Once a diagnosis of Alzheimer's dementia is made, it is categorized based 
on time of onset. Onset after the age of 65 is classified as late onset, and 
diagnosis before the age of 65 is considered early onset. Alzheimer's affects 
individuals typically only after the age of 65, but can affect individuals as early 
as the age of 40 (Canadian Alzheimer's Society, 2005). The only way to 
definitively diagnose an individual with Alzheimer's, again to the exclusion of 
other forms of dementia, is by post-mortem tissue analysis. The brains of 
individuals with Alzheimer's show high levels of cell death, buildup of β-amyloid 
protein plaques, and neurofibrillary tangles (Knox & Gekoski, 2003). These 
‘plaques and tangles' are characteristic of and invariably indicate Alzheimer's 
pathology, and post-mortem diagnosis can be made based on their presence. 
Raber, Huang and Ashford (2003) have shown that neural degeneration is not 
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isolated but centres heavily on the hippocampus, a structure pivotal to the 
formation of new memories. Therefore hippocampal degeneration is another 
key marker to the presence of Alzheimer's dementia. 
Cause 
As with any complex disorder with such a wide array of symptoms, there is 
no single causal factor in Alzheimer's dementia. It is best treated as a sum of 
factors, most of which fall under the categories of genetic predisposition and 
environmental conditions. The broadest category of risk is genetic, specifically 
carried on the apolipoprotein E (apoE) gene (Canadian Alzheimer's Society, 
2005). Research summarized by Raber, Huang and Ashford (2006) shows that 
the four variants (ε1- ε4) are associated with different risks of developing 
Alzheimer's dementia. The ε4 variant in particular carries the highest risk of 
developing Alzheimer's as well as greater risk of early onset. While only 2% of 
the US population is homozygous for the ε4 allele (ε4/4), they account for 16% 
of Alzheimer's cases. Heterozygotes for this allele (ε3/4) account for 42% of 
Alzheimer's cases, and individuals homozygous for the ε3 allele (ε3/3) account 
for 35% of the remaining cases. Interestingly, the ε2 allele has been associated 
with a degree of protection from developing Alzheimer's disease (Raber et al., 
2006). The disproportionately high percentage of cases in individuals 
homozygous or heterozygous with the ε4 allele has prompted research into the 
function of the apoE protein, and how structural variants coded for by different 
alleles affect Alzheimer's pathology. 
The role of the apoE protein in the body is typically to bind and transport 
serum cholesterol for processing (Bales et al., 1999). The different apoE 
variants all serve this function with varying efficacy. Raber, Huang and Ashford 
(2004) postulate that the ε4 variant is ineffective at serving this function, leading 
to higher serum levels of cholesterol. This predisposes ε4 carriers to 
cardiovascular disease due to higher levels of cholesterol deposition in the 
blood stream (atherosclerosis). The mechanism by which the ε4 allele is 
thought to lead to Alzheimer's is not as clear cut. In studies with transgenic 
mice expressing the Alzheimer's genotype, the presence of apoE is sufficient to 
induce the deposition of amyloid-β plaques in the brain (Bales et al., 1999). The 
variant apoE proteins coded for by ε1- ε4 again vary in efficacy of amyloid-β 
binding, with ε4 binding the most at homeostatic pH (Strittmatter et al., 1993). 
The mechanism by which amyloid-β proteins are subsequently deposited into 
plaques is unknown, but has devastating consequences. 
Firstly, the deposition of amyloid-β plaques induces internalization of N-
methyl-D-aspartate (NMDA) receptors in the cortex (Snyder et al., 2005). The 
NMDA glutamate receptors are pivotal for the process of long-term potentiation: 
NMDA receptor internalization could account for the learning and memory 
deficits characteristic of Alzheimer's dementia. Secondly Strohmeyer, 
Kovelowski, Mastroeni, Leonard, Grover and Rogers (2005) have shown that 
the presence of amyloid plaques induces an immune response by the microglia 
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in the brain. Subsequent release of inflammatory cytokines such as 
interleukin-6 and tumour necrosis factor-α causes a delocalized inflammation, 
which invariably leads to neuronal damage (Strohmeyer et al., 2005). This 
phenomenon is ostensibly responsible for the emaciated cortex and enlarged 
ventricles of individuals with Alzheimer's. The delocalization of this effect would 
also account for the variety of cognitive deficits seen in Alzheimer's dementia. 
Raber, Huang and Ashford (2004) also link the development of neurofibrillary 
tangles with different apoE isoforms, but not to the same degree as amyloid-β 
plaques. The ε4 allele is again associated with elevated formation of tangles 
characteristic of Alzheimer's pathology though the mechanism and clinical 
significance are still unclear (Raber et al., 2004). 
Epidemiological surveys have given important clues as to environmental 
factors that influence the development of Alzheimer's dementia. The most 
notorious of these theories is level of exposure to metal ions. For example, 
epidemiological studies report that individuals living in areas with aluminum 
content in the water are more susceptible to developing Alzheimer's (Knox & 
Gekoski, 2003). Interestingly, this theory is somewhat supported by the 
‘plaques and tangles' model: amyloid-β plaque deposition is increased in 
relation to exposure to other metal ions such as copper and zinc, as shown by 
Raber, Huang and Ashford (2004). Exposure to high levels of aluminum has 
also been associated with increased formation of neurofibrillary tangles (Knox 
and Gekoski, 2003). 
Infection with certain pathogens has also been associated with the 
development of Alzheimer's, especially herpes simplex virus type 1 (oro-facial 
herpes, HSV-1) and tuberculosis (Knox and Gekoski, 2003). While both 
infections are normally contained in the body, under certain circumstances they 
can become delocalized and infect brain tissue. The resulting encephalitis 
causes substantial damage, similar to that of the microglial inflammatory 
response to amyloid-β plaques. Since severe encephalitis invariably leads to a 
degree of dementia, it is uncertain whether HSV-1 and tuberculosis infections 
induce or aggravate Alzheimer's, or are symptomatically the same. 
Interestingly, Helicobacter pylori, the gastrointestinal parasite implicated in 
causing the majority of peptic ulcers, has also been correlated with 
development of Alzheimer's (Kountouras et al., 2005). The mechanism is 
unknown and there have been no reported cases of H. pylori encephalitis. The 
gradual degradation of the immune system is a natural part of aging, and the 
elderly often succumb to opportunistic infection or the reactivation of chronic 
infections such as HSV-1, tuberculosis and possibly H. pylori. With a deficient 
immune system, these infections can delocalize to the brain and cause 
encephalitis and dementia. There is little research done on the interaction 
between the aging immune system and the aging brain beyond these 
epidemiological studies, and potentially a great deal more to be learned in this 
area. 
Treatment 
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Presently, all treatment of Alzheimer's (medical or therapeutical) is targeted 
at decreasing expression of negative symptoms and cognitive decline. There is 
no known way to reverse the damage or inhibit the formation of plaques and 
tangles. Individuals with Alzheimer's often suffer from depression as well, 
necessitating various treatments for that and other comorbid conditions (Mace 
& Rabins, 1999; Knox & Gekoski, 2003).  
The first major group of drug treatments is the cognitive enhancers. Of 
these, acetylcholinesterase (AChE) inhibitors were the first category of drugs 
developed to treat individuals with Alzheimer's. Examples of these drugs 
include donepezil, galantamine, and the now outdated tacrine (Canadian 
Alzheimer's Society, 2005). By blocking its natural metabolism, these drugs 
allow more acetylcholine to remain in the synapses for longer and stimulate 
cholinergic receptors more potently. This is an interesting method of 
approaching treatment: While individuals with Alzheimer's do indeed have 
decreased cholinergic function, Kumar, Durai and Jobe (1998) show that they 
also have lower functioning of several of the major cortical neurotransmitters 
(e.g. serotonin, norepinephrine and certain neuropeptides). It is not yet proven 
that acetylcholine is even involved in the pathology of Alzheimer's; lowered 
cholinergic function could be equally well explained by the massive neuronal 
death in the cortex. AChE inhibitor use therefore seems unjustified in treating 
Alzheimer's. However stimulation of the cholinergic system, specifically the 
nicotinic acetylcholine receptors, improves functional memory (Giocomo & 
Hasselmo, 2005). In fact the stimulation of this system by smoking tobacco has 
been shown to be an epidemiological protective factor against the development 
of Alzheimer's (Knox & Gekoski). This relationship seems to vindicate the use 
of AChE inhibitors, if only to delay the cognitive decline associated with 
Alzheimer's dementia. AChE inhibitors can have undesirable side effects, such 
as anxiety, gastrointestinal problems, drowsiness, and in some cases liver 
toxicity (Canadian Alzheimer's Society, 2005). 
A novel method of treatment involves NMDA antagonism. Strohmeyer, 
Kovelowski, Mastroeni, Leonard, Grover and Rogers (2005) show that in 
inflammatory reactions in the brain, neurons undergo glutamate-induced 
excitotoxic cell death . The death of these neurons causes further inflammation, 
creating a cascade effect and compounding damage similar to a stroke model. 
Excitotoxic cell death is caused by excessive calcium ion influx through the 
NMDA glutamate receptor (Strohmeyer et al., 2005). Floden, Li and Combs 
(2005) conjecture that the influx of calcium is toxic to the cell, activating both 
apoptotic and necrotic pathways. The hope of NMDA blockers, specifically the 
new drug memantine, is to prevent this from occuring. Memantine is thought to 
bind the NMDA receptor, blocking the voltage gated ion channel with a higher 
affinity than the native magnesium ion (Floden et al., 2005). The high affinity of 
the drug for the channel itself decreases influx by physically blocking calcium 
ions from entering the cell. This drug, conversely, has relatively benign side 
effects ranging from headaches to drowsiness (Canadian Alzheimer's Society, 
2005). It can be safely used in conjunction with AChE inhibitors for maximum 
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effect. 
Losing one's memory can have devastating effects on an individual, and 
frequently results in depression and in some cases psychosis (Jeste & Finkel, 
2000; Mace & Rabins, 1999). Drug therapy for individuals with Alzheimer's 
dementia and comorbid conditions accordingly includes a course of 
antidepressants or antipsychotics. The complications arising from peripheral 
conditions also make behavioural therapy a useful treatment (Knox & Gekoski, 
2003). While behavioural therapy cannot in any way cure or influence the 
biological condition, they facilitate care of individuals with Alzheimer's. 
Counseling for caregivers is also available to help them cope with the 
demanding task of caring for these individuals. These also help inform 
caregivers on how to promote the quality of life and safety of individuals with 
Alzheimer's (Knox & Gekoski, 2003). This helps caregivers to cope with 
behavioural symptoms in a natural manner, taking some of the emphasis off of 
medications. 
Social/Ethical Issues 
Canada and the Western world in general are currently in the wake of a 
massive population boom. The ‘baby boomer' generation is composed of 
individuals who will soon be classified as senior citizens. Following current 
demographic trends, in 5 years individuals over the age of 65 will represent 
14.1% of the Canadian population, the highest percentage in history (Knox & 
Gekoski, 2003). While Alzheimer's is not in any way a normal part of aging, its 
prevalence increases exponentially with age. The number of individuals with 
Alzheimer's will likely increase at a rate proportional to the increase in elderly 
individuals. To compound an already troublesome situation, life expectancies 
continue to rise following advances in medicare. In summary, the prevalence of 
Alzheimer's will increase significantly in the next few decades, as will the need 
for long-term care for those suffering from it. The burden of providing this care 
will fall on the under-represented economically productive demographic. This 
population shift brings up the moral dilemma of how to treat such a large 
number of people. Providing good quality of care for individuals with 
Alzheimer's is becoming increasingly unfeasible due to the rising demand for 
long-term care facilities. The low birth rate of the baby-boomers means that 
there are fewer young relatives to care for their elderly parents, which can be a 
psychologically demanding task. Conversely, the cheapest and most viable 
option, care homes, typically entails poorer quality of life for individuals with 
mental disorders. Western society needs to reevaluate moral treatment of the 
elderly in order to ensure proper care. 
Currently, our society holds in the highest regard the qualities of productivity 
and rationality (Post, 1995). An individual suffering from Alzheimer's is almost 
without exception unable to work, and has lost (or is fast losing) ‘rationality'. By 
current standards, individuals with Alzheimer's contribute nothing worthwhile to 
society. Similarly, in their campaigns to euthanize the mentally ill the Nazis 
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described the existence of the mentally ill as “lebenumwertes Leben” - Life 
unworthy of life (Post, 1995). This crude parallel demonstrates how though in 
Canada we do not euthanize the mentally ill, we hold the very same values that 
would justify doing so. Furthermore, it calls into question what we really mean 
by ‘rational' or ‘productive'. The problem of subjective perception once again 
arises: We base our values on what we ourselves would do and the qualities 
that we value in ourselves. This is a typical but unfair way of judging others: 
The decision making demographic typically does not suffer from 
neurodegenerative diseases of aging such as Alzheimer's. Assuring proper 
care for individuals with Alzheimer's will first necessitate a reevaluation of what 
it means to be a valued member of society. 
A suggestion to circumvent the issue of quality of life is to legalize 
euthanasia. Allowing humane death could give individuals with Alzheimer's the 
choice to escape from a chronic and terminal illness. Euthanasia in the case of 
Alzheimer's is a particularly troublesome issue. Firstly, requests for euthanasia 
in these individuals are rare (Post, 1995). This is likely due to cognitive 
degradation, misunderstanding and confusion as to their situation. Allowing 
caregivers to opt for euthanization of a relative with Alzheimer's dementia on 
his or her behalf is another possibility, but raises weighty moral issues. This 
predicament again calls into question societal values of productivity and 
rationality, and whether we have the right to impose our values on individuals 
who may not share our point of view. The question of euthanasia also requires 
that we are able to quantify suffering in another individual in order to make the 
best decision on their behalf, which is theoretically impossible. Most obviously, 
allowing euthanasia presumes that we as a society have the moral authority to 
end life. These problems currently have no answer. Caring properly for the 
growing number of individuals with Alzheimer's will no doubt call into question 
our ethics as a society. 
There are an alarming number of individuals who will develop Alzheimer's 
dementia in the next few decades. Within 10 years, an individual can cease 
being a contributing member of society and become a substantial burden on 
relatives and caregivers. As the elderly population grows, so does the need to 
understand the mechanisms of this disease. Novel treatments and diagnostic 
measures are increasingly geared at making it a more manageable disease for 
caregivers as well as those suffering from it. Researchers have made large 
advances in elucidating the exact cause of Alzheimer's and continue to make 
promising discoveries, but there is little hope of a cure. Alzheimer's dementia is 
a looming problem that needs to be fully explored by science and research, but 
always keeping in mind that those who suffer from it are human beings and are 
valuable to society. 
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